Evidence, Safety, and the Regulatory Landscape GLP-1 microdosing is biologically plausible, but its safety and effectiveness have not been validated in randomized clinical trials
doi: 10.3389/fendo.2023.1133000 Received 28 December 2022 Accepted 13 March 2023 Published 24 March 2023 Volume 14 - 2023 Edited by Silvia Martina Ferrari, University of Pisa, Italy Reviewed by Sabrina Rosaria Paparo, University of Pisa, Italy
Answer: Epithalon is generally described as well tolerated in the available research, but it is not FDA-approved as a drug, long-term human safety data are limited, and it should only be used under medical supervision
We recognize the important roles that pharmaceutical compounding and telehealth play in the health care delivery system, helping to ensure access to FDA-approved products and filling a need for more customized treatments, Durbin and Marshall wrote